Pieris Pharmaceuticals (NSDQ:PIRS) today priced an underwritten public offering of 5.5 million shares of its common stock at $8.00 per share.
The company said it expects to generate $44 million from the offering, which it will use to fund the pre-clinical and clinical development of its pipeline.
Get the full story at our sister site, Drug Delivery Business News.
The post Pieris Pharmaceuticals prices $44m public offering appeared first on MassDevice.